{"id":876473,"date":"2025-08-18T07:20:24","date_gmt":"2025-08-18T11:20:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\/"},"modified":"2025-08-18T07:20:24","modified_gmt":"2025-08-18T11:20:24","slug":"fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\/","title":{"rendered":"FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-top:5pt;text-align:justify\">\n          <em>Sale of FibroGen China remains on track to close in 3Q 2025<\/em><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">SAN FRANCISCO, Aug.  18, 2025  (GLOBE NEWSWIRE) &#8212; FibroGen, Inc.\u00a0(NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited, pursuant to the Share Purchase Agreement, dated February 20, 2025.<\/p>\n<p align=\"justify\">The closing of the transaction remains subject to other contractual closing conditions and deliverables and remains on track to close in the third quarter of 2025.<\/p>\n<p>\n        <strong>About FibroGen<\/strong><br \/>\n        <br \/>FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (\u7231\u745e\u5353<sup>\u00ae<\/sup>, EVRENZO\u2122) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5mH7qUvBErOqcWVlaNJOO6rLL9lk-vPur1-cJWsftd-f88-PBpgYMUEIk9AsQI__MAHY1ZZ-ztuj0V-wx4ftiJREoikzwyu1niYrnHZVc78=\" rel=\"nofollow\" target=\"_blank\">www.fibrogen.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This release contains forward-looking statements regarding FibroGen\u2019s strategy, future plans and prospects, including statements regarding its commercial products and clinical programs. These forward-looking statements include, but are not limited to, statements regarding regulatory interactions, the closing of the sale of FibroGen China, and statements about FibroGen\u2019s plans and objectives. These forward-looking statements are typically identified by use of terms such as \u201cmay,\u201d \u201cwill\u201d, \u201cshould,\u201d \u201con track,\u201d \u201ccould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201ccontinue\u201d and similar words, although some forward-looking statements are expressed differently. FibroGen\u2019s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in FibroGen\u2019s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and FibroGen undertakes no obligation to update any forward-looking statement in this press release, except as required by law.<\/p>\n<p>\n        <strong>For Investor Inquiries:<\/strong><br \/>\n        <br \/>David DeLucia, CFA<br \/>Senior Vice President and Chief Financial Officer<br \/>ir@fibrogen.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzY1NSM3MTAyODIzIzIwMDc5NjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmVhMGQzOGEtNGZjYi00Yjg0LWJiNTItMTBiZjc4MTE2ODE0LTEwMTk1MzYtMjAyNS0wOC0xOC1lbg==\/tiny\/FibroGen-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) &#8212; FibroGen, Inc.\u00a0(NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited, pursuant to the Share Purchase Agreement, dated February 20, 2025. The closing of the transaction remains subject to other contractual closing conditions and deliverables and remains on track to close in the third quarter of 2025. About FibroGen FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (\u7231\u745e\u5353\u00ae, EVRENZO\u2122) is currently approved in China, Europe, Japan, and numerous other countries for the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-876473","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) &#8212; FibroGen, Inc.\u00a0(NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited, pursuant to the Share Purchase Agreement, dated February 20, 2025. The closing of the transaction remains subject to other contractual closing conditions and deliverables and remains on track to close in the third quarter of 2025. About FibroGen FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (\u7231\u745e\u5353\u00ae, EVRENZO\u2122) is currently approved in China, Europe, Japan, and numerous other countries for the &hellip; Continue reading &quot;FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-18T11:20:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzY1NSM3MTAyODIzIzIwMDc5NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation\",\"datePublished\":\"2025-08-18T11:20:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\\\/\"},\"wordCount\":439,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxMzY1NSM3MTAyODIzIzIwMDc5NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\\\/\",\"name\":\"FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxMzY1NSM3MTAyODIzIzIwMDc5NjM=\",\"datePublished\":\"2025-08-18T11:20:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxMzY1NSM3MTAyODIzIzIwMDc5NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxMzY1NSM3MTAyODIzIzIwMDc5NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\/","og_locale":"en_US","og_type":"article","og_title":"FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation - Market Newsdesk","og_description":"Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) &#8212; FibroGen, Inc.\u00a0(NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited, pursuant to the Share Purchase Agreement, dated February 20, 2025. The closing of the transaction remains subject to other contractual closing conditions and deliverables and remains on track to close in the third quarter of 2025. About FibroGen FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (\u7231\u745e\u5353\u00ae, EVRENZO\u2122) is currently approved in China, Europe, Japan, and numerous other countries for the &hellip; Continue reading \"FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-18T11:20:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzY1NSM3MTAyODIzIzIwMDc5NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation","datePublished":"2025-08-18T11:20:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\/"},"wordCount":439,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzY1NSM3MTAyODIzIzIwMDc5NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\/","name":"FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzY1NSM3MTAyODIzIzIwMDc5NjM=","datePublished":"2025-08-18T11:20:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzY1NSM3MTAyODIzIzIwMDc5NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxMzY1NSM3MTAyODIzIzIwMDc5NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-announces-approval-of-sale-of-fibrogen-china-to-astrazeneca-by-the-china-state-administration-for-market-regulation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/876473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=876473"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/876473\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=876473"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=876473"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=876473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}